Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: A role in alzheimer's disease?

Zhiheng Liu, Haihao Zhu, Guang Guang Fang, Kathryn Walsh, Mkaya Mwamburi, Benjamin Wolozin, Samer O. Abdul-Hay, Tsuneya Ikezu, Malcolm A. Leissring, Wei Qiao Qiu

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Sporadic Alzheimer's disease (AD) patients have low amyloid-β peptide (Aβ) clearance in the central nervous system. The peripheral Aβ clearance may also be important but its role in AD remains unclear. We aimed to study the Aβ degrading proteases including insulin degrading enzyme (IDE), angiotensin converting enzyme (ACE) and others in blood. Using the fluorogenic substrate V (a substrate of IDE and other metalloproteases), we showed that human serum degraded the substrate V, and the activity was inhibited by adding increasing dose of Aβ. The existence of IDE activity was demonstrated by the inhibition of insulin, amylin, or EDTA, and further confirmed by immunocapture of IDE using monoclonal antibodies. The involvement of ACE was indicated by the ability of the ACE inhibitor, lisinopril, to inhibit the substrate V degradation. To test the variations of substrate V degradation in humans, we used serum samples from a homebound elderly population with cognitive diagnoses. Compared with the elderly who had normal cognition, those with probable AD and amnestic mild cognitive impairment (amnestic MCI) had lower peptidase activities. Probable AD or amnestic MCI as an outcome remained negatively associated with serum substrate V degradation activity after adjusting for the confounders. The elderly with probable AD had lower serum substrate V degradation activity compared with those who had vascular dementia. The blood proteases mediating Aβ degradation may be important for the AD pathogenesis. More studies are needed to specify each Aβ degrading protease in blood as a useful biomarker and a possible treatment target for AD.

Original languageEnglish (US)
Pages (from-to)329-340
Number of pages12
JournalJournal of Alzheimer's Disease
Volume29
Issue number2
DOIs
StatePublished - 2012

Fingerprint

Insulysin
Amyloid
Alzheimer Disease
Peptide Hydrolases
Serum
Peptidyl-Dipeptidase A
Islet Amyloid Polypeptide
Lisinopril
Vascular Dementia
Aptitude
Metalloproteases
Fluorescent Dyes
Angiotensin-Converting Enzyme Inhibitors
Edetic Acid
Cognition
Central Nervous System
Biomarkers
Monoclonal Antibodies
Insulin

Keywords

  • Aβ degradation
  • Alzheimer's disease
  • angiotensin converting enzyme
  • insulin degrading enzyme
  • protease
  • serum

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum : A role in alzheimer's disease? / Liu, Zhiheng; Zhu, Haihao; Fang, Guang Guang; Walsh, Kathryn; Mwamburi, Mkaya; Wolozin, Benjamin; Abdul-Hay, Samer O.; Ikezu, Tsuneya; Leissring, Malcolm A.; Qiu, Wei Qiao.

In: Journal of Alzheimer's Disease, Vol. 29, No. 2, 2012, p. 329-340.

Research output: Contribution to journalArticle

Liu, Z, Zhu, H, Fang, GG, Walsh, K, Mwamburi, M, Wolozin, B, Abdul-Hay, SO, Ikezu, T, Leissring, MA & Qiu, WQ 2012, 'Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: A role in alzheimer's disease?', Journal of Alzheimer's Disease, vol. 29, no. 2, pp. 329-340. https://doi.org/10.3233/JAD-2011-111472
Liu, Zhiheng ; Zhu, Haihao ; Fang, Guang Guang ; Walsh, Kathryn ; Mwamburi, Mkaya ; Wolozin, Benjamin ; Abdul-Hay, Samer O. ; Ikezu, Tsuneya ; Leissring, Malcolm A. ; Qiu, Wei Qiao. / Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum : A role in alzheimer's disease?. In: Journal of Alzheimer's Disease. 2012 ; Vol. 29, No. 2. pp. 329-340.
@article{ddca539cfd7e406596279bdb5321b20e,
title = "Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: A role in alzheimer's disease?",
abstract = "Sporadic Alzheimer's disease (AD) patients have low amyloid-β peptide (Aβ) clearance in the central nervous system. The peripheral Aβ clearance may also be important but its role in AD remains unclear. We aimed to study the Aβ degrading proteases including insulin degrading enzyme (IDE), angiotensin converting enzyme (ACE) and others in blood. Using the fluorogenic substrate V (a substrate of IDE and other metalloproteases), we showed that human serum degraded the substrate V, and the activity was inhibited by adding increasing dose of Aβ. The existence of IDE activity was demonstrated by the inhibition of insulin, amylin, or EDTA, and further confirmed by immunocapture of IDE using monoclonal antibodies. The involvement of ACE was indicated by the ability of the ACE inhibitor, lisinopril, to inhibit the substrate V degradation. To test the variations of substrate V degradation in humans, we used serum samples from a homebound elderly population with cognitive diagnoses. Compared with the elderly who had normal cognition, those with probable AD and amnestic mild cognitive impairment (amnestic MCI) had lower peptidase activities. Probable AD or amnestic MCI as an outcome remained negatively associated with serum substrate V degradation activity after adjusting for the confounders. The elderly with probable AD had lower serum substrate V degradation activity compared with those who had vascular dementia. The blood proteases mediating Aβ degradation may be important for the AD pathogenesis. More studies are needed to specify each Aβ degrading protease in blood as a useful biomarker and a possible treatment target for AD.",
keywords = "Aβ degradation, Alzheimer's disease, angiotensin converting enzyme, insulin degrading enzyme, protease, serum",
author = "Zhiheng Liu and Haihao Zhu and Fang, {Guang Guang} and Kathryn Walsh and Mkaya Mwamburi and Benjamin Wolozin and Abdul-Hay, {Samer O.} and Tsuneya Ikezu and Leissring, {Malcolm A.} and Qiu, {Wei Qiao}",
year = "2012",
doi = "10.3233/JAD-2011-111472",
language = "English (US)",
volume = "29",
pages = "329--340",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum

T2 - A role in alzheimer's disease?

AU - Liu, Zhiheng

AU - Zhu, Haihao

AU - Fang, Guang Guang

AU - Walsh, Kathryn

AU - Mwamburi, Mkaya

AU - Wolozin, Benjamin

AU - Abdul-Hay, Samer O.

AU - Ikezu, Tsuneya

AU - Leissring, Malcolm A.

AU - Qiu, Wei Qiao

PY - 2012

Y1 - 2012

N2 - Sporadic Alzheimer's disease (AD) patients have low amyloid-β peptide (Aβ) clearance in the central nervous system. The peripheral Aβ clearance may also be important but its role in AD remains unclear. We aimed to study the Aβ degrading proteases including insulin degrading enzyme (IDE), angiotensin converting enzyme (ACE) and others in blood. Using the fluorogenic substrate V (a substrate of IDE and other metalloproteases), we showed that human serum degraded the substrate V, and the activity was inhibited by adding increasing dose of Aβ. The existence of IDE activity was demonstrated by the inhibition of insulin, amylin, or EDTA, and further confirmed by immunocapture of IDE using monoclonal antibodies. The involvement of ACE was indicated by the ability of the ACE inhibitor, lisinopril, to inhibit the substrate V degradation. To test the variations of substrate V degradation in humans, we used serum samples from a homebound elderly population with cognitive diagnoses. Compared with the elderly who had normal cognition, those with probable AD and amnestic mild cognitive impairment (amnestic MCI) had lower peptidase activities. Probable AD or amnestic MCI as an outcome remained negatively associated with serum substrate V degradation activity after adjusting for the confounders. The elderly with probable AD had lower serum substrate V degradation activity compared with those who had vascular dementia. The blood proteases mediating Aβ degradation may be important for the AD pathogenesis. More studies are needed to specify each Aβ degrading protease in blood as a useful biomarker and a possible treatment target for AD.

AB - Sporadic Alzheimer's disease (AD) patients have low amyloid-β peptide (Aβ) clearance in the central nervous system. The peripheral Aβ clearance may also be important but its role in AD remains unclear. We aimed to study the Aβ degrading proteases including insulin degrading enzyme (IDE), angiotensin converting enzyme (ACE) and others in blood. Using the fluorogenic substrate V (a substrate of IDE and other metalloproteases), we showed that human serum degraded the substrate V, and the activity was inhibited by adding increasing dose of Aβ. The existence of IDE activity was demonstrated by the inhibition of insulin, amylin, or EDTA, and further confirmed by immunocapture of IDE using monoclonal antibodies. The involvement of ACE was indicated by the ability of the ACE inhibitor, lisinopril, to inhibit the substrate V degradation. To test the variations of substrate V degradation in humans, we used serum samples from a homebound elderly population with cognitive diagnoses. Compared with the elderly who had normal cognition, those with probable AD and amnestic mild cognitive impairment (amnestic MCI) had lower peptidase activities. Probable AD or amnestic MCI as an outcome remained negatively associated with serum substrate V degradation activity after adjusting for the confounders. The elderly with probable AD had lower serum substrate V degradation activity compared with those who had vascular dementia. The blood proteases mediating Aβ degradation may be important for the AD pathogenesis. More studies are needed to specify each Aβ degrading protease in blood as a useful biomarker and a possible treatment target for AD.

KW - Aβ degradation

KW - Alzheimer's disease

KW - angiotensin converting enzyme

KW - insulin degrading enzyme

KW - protease

KW - serum

UR - http://www.scopus.com/inward/record.url?scp=84859394857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859394857&partnerID=8YFLogxK

U2 - 10.3233/JAD-2011-111472

DO - 10.3233/JAD-2011-111472

M3 - Article

C2 - 22232014

AN - SCOPUS:84859394857

VL - 29

SP - 329

EP - 340

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -